1. ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets
- Author
-
Jennifer A. Barr, Kristen D. McAuley, Petrus Jansen van Vuren, Gough G. Au, Cameron R. Stewart, Sarah Edwards, Willy W. Suen, Brenton Rowe, Jean Payne, Hannah Bender, Christina L. Rootes, Nagendrakumar Balasubramanian Singanallur, Kathie Burkett, Matthew J. Neave, Teresa Lambe, Vittoria Stevens, Kim Halpin, Peter A. Durr, Glenn A. Marsh, Duane Walter, Clare Holmes, Suzanne Lowther, Elisha Soldani, Alexander J. McAuley, Seshadri S. Vasan, Daniel S. Layton, Matthew P. Bruce, Mary Tachedjian, Shawn Todd, Lee Trinidad, John Bingham, Sarah Jane Riddell, Rachel Layton, Sarah C. Gilbert, William S. J. Horman, Jenni Harper, Victoria Boyd, Kate Maynard, Naomi Watson, Teresa Eastwood, Trevor W. Drew, Tamara J Gough, Timothy Poole, and Sheree Brown
- Subjects
0301 basic medicine ,2019-20 coronavirus outbreak ,Coronavirus disease 2019 (COVID-19) ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Immunology ,Article ,03 medical and health sciences ,0302 clinical medicine ,Pandemic ,Medicine ,Pharmacology (medical) ,030212 general & internal medicine ,Adverse effect ,RC254-282 ,Pharmacology ,Vaccines ,business.industry ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC581-607 ,Clinical trial ,030104 developmental biology ,Infectious Diseases ,Viral infection ,Nasal administration ,Immunologic diseases. Allergy ,business ,Viral load - Abstract
Vaccines against SARS-CoV-2 are likely to be critical in the management of the ongoing pandemic. A number of candidates are in Phase III human clinical trials, including ChAdOx1 nCoV-19 (AZD1222), a replication-deficient chimpanzee adenovirus-vectored vaccine candidate. In preclinical trials, the efficacy of ChAdOx1 nCoV-19 against SARS-CoV-2 challenge was evaluated in a ferret model of infection. Groups of ferrets received either prime-only or prime-boost administration of ChAdOx1 nCoV-19 via the intramuscular or intranasal route. All ChAdOx1 nCoV-19 administration combinations resulted in significant reductions in viral loads in nasal-wash and oral swab samples. No vaccine-associated adverse events were observed associated with the ChAdOx1 nCoV-19 candidate, with the data from this study suggesting it could be an effective and safe vaccine against COVID-19. Our study also indicates the potential for intranasal administration as a way to further improve the efficacy of this leading vaccine candidate.
- Published
- 2021